Tag: venture capital
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-
Infographic – Global Q3 Venture Funding Levels Off
Global venture investment dollars in the third quarter of 2023 rose somewhat from the previous quarter, but remained at about the same level for the past 12 months.
-
Biomanufacturing Company Gains $9.5M in Early Funds
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round.
-
Industry-Academic Center to Boost Rare Disease Therapies
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K.
-
University Start-Up Developing Inhaled Gene Therapies
A new company spun-off from a university lab consortium is advancing gene therapies delivered through the lungs to treat rare inherited respiratory diseases.
-
Autoimmune Neuro Disease Start-Up Raises $58M
A new company developing treatments for neurological and psychiatric diseases from aberrant immune system activity is raising $58 million in seed funds.
-
Venture Firm, Cancer Center Start Antibody Biotech Company
A company formed by M.D. Anderson Cancer Center and Panacea Venture plans to develop synthetic antibodies as treatments addressing new cancer targets.
-
HHS Directs $100M for Covid-19 Venture Investments
The Department of Health and Human Services is allocating $100 million for venture investments in new technologies to prepare for future threats from Covid-19.
-
Infographic – Some Good Corporate Venture Fund News
Since the start of 2021, most news has been gloomy about venture investments, but a report last week suggests corporate venture capital funding worldwide is picking up.
-
Long-Acting Drug Start-Up Raises $4M in Seed Funds
A new company with a process using artificial intelligence and robotics to speed development of sustained release drugs is raising $4 million in seed funds.